New trial
Phase 1b Venetoclax BCL-2 inhibitor trial comparing HMA versus intensive induction in AML
- Trial ID
- NCT07060001 on ClinicalTrials.gov
- Cancer type
- AML: Acute Myeloid Leukemia
- Stage of research
- Exploratory
- Published in
- New in Oncology - Aug 1, 2025
This therapeutic trial at The Methodist Hospital Research Institute evaluates a novel blood-based 5hmC biomarker in adults with de novo AML by comparing HMA regimens (azacitidine or decitabine plus venetoclax with DNA methylation and BCL-2 inhibition) versus standard intensive induction (cytarabine with anthracycline). Blood sampling at defined intervals guides post-induction treatment, with endpoints including MRD negativity, remission duration, event-free survival, and overall survival.
More in acute myeloid leukemia and MDS
-
Trial result · Oct 22, 2026 · NCT03672539
CPX-351 (liposomal daunorubicin/cytarabine) + CD33-targeted gemtuzumab ozogamicin delivers 19% CRc in heavily pretreated R/R AML -
New trial · Oct 15, 2026 · NCT07809906
Phase 1 ORM-1153 CD123-directed degrader-antibody conjugate delivers a GSPT1-degrading payload in hematologic malignancies -
Trial result · Sep 17, 2026 · NCT02159495
CD123 CAR-T Delivers ~27% CR/CRi in Post-alloHCT AML With Manageable CRS/Neurotoxicity -
New trial · Sep 10, 2026 · NCT07581002
Phase 2/3 Pivekimab sunirine CD123-targeted ADC (IGN payload) + venetoclax/azacitidine in AML -
New trial · Sep 10, 2026 · NCT07780565
Phase 1b monzosertib CDC7 kinase inhibitor tests azole–drug interaction dosing in AML/MDS